POLISCOPE
Back to feed
NewsLos Angeles Times – PoliticsNovember 10, 2026Los Angeles County

California voters approve Proposition 38 to issue $8.4 billion in bonds for medical research

Photo: Los Angeles Times – Politics

California voters passed Proposition 38, authorizing the state to issue $8.4 billion in bonds to fund immunology and immunotherapy research for chronic diseases. The measure requires at least half of the funds to go toward research on cancer, heart disease, and Alzheimer's disease, and allows a partnership with a designated research institute. Taxpayers will face an estimated annual cost of $500 million to $600 million for roughly 20 years to repay the bonds.

Read the full story at Los Angeles Times – Politics

Why It Matters

State taxpayers will take on an annual debt repayment cost of $500 million to $600 million for an anticipated 20 years to fund medical research grants and a designated research institute partnership.

Key Facts

  • Voters approved Proposition 38, authorizing $8.4 billion in state bonds for immunology and immunotherapy research.
  • At least $4.2 billion must be dedicated to immunology research focusing on cancer, heart disease, and Alzheimer's disease.
  • The measure authorizes a state partnership with an unnamed research institute selected by the California Department of Public Health, allocating half of the bond revenue to it.
  • Taxpayers will incur an increased cost of $500 million to $600 million annually for an anticipated 20 years to repay the bonds.
  • Philanthropist Gary K. Michelson wrote the proposition and contributed $45 million to support the campaign.
  • Remaining funds will be distributed through competitive research grants administered by a council from University of California campuses, universities, and nonprofit research institutions.
  • Opponents argued the measure saddles taxpayers with decades of debt and creates grant criteria that currently fit only one institute.
  • Supporters noted the funding helps offset federal research funding cuts that have disrupted clinical trials.

Who's Mentioned